Raleigh, N.C., June 1, 2012 - INC Research, LLC, a therapeutically focused clinical research organization (CRO) with a Trusted Process® for delivering reliable results, is attending the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting from June 1 - 5 at McCormick Place in Chicago to discuss how ASCO's blueprint for transforming clinical and translational cancer research (Accelerating Progress Against Cancer) will impact drug pipelines.
"It's been 40 years since the signing of the National Cancer Act and while tremendous progress has been made, the war on cancer continues," said Nicholas Kenny, PhD, executive vice president and general manager, Global Oncology and Hematology at INC Research. "We are excited to be part of this year's ASCO and its Accelerating Progress Against Cancer initiative to discuss innovative oncology approaches such as including personalized medicine, nanotechnology, stem cells, and biomarkers and epigenetics. An important goal for us has been to recognize and appreciate the local issues and complexities of cancer clinical trials. In doing so, we're able to tailor each project according to the individual requirements of the study and, most importantly, of the patients who participate in that study."
Having helped sponsors conduct cancer clinical trials since 2001, INC Research has a dedicated team of almost 400 oncology specialists, within a larger 5,000-strong organization, focused exclusively on clinical trials in oncology. Its experience across a broad range of therapeutic modalities and tumor types, allows INC Research to plan and execute cancer clinical trials with the highest degree of operational efficiency, while still having the advanced medical and regulatory knowledge to insure that trials are conducted with the highest level of quality. Through its Phase I to IV oncology services, first-in-patient expertise and a commitment to innovation, INC Research offers support and guidance at all levels and stages of clinical development.
For more information about INC Research's oncology research capabilities and Trusted Process methodology can support your clinical development plans, please visit booth #15087 at ASCO or download our oncology fact sheet.
About INC Research
INC Research is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in all therapeutic areas and innovative pediatric and women's health trials. The company's Trusted Process® methodology and therapeutic foresight lead customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, NC. For more information, please visit www.incresearch.com or follow us at @inc_research.
Contact: Lori Dorer, Media (513) 345-1685